Log in or Sign up for Free to view tailored content for your specialty!
Neurocritical Care News
Teleneurology program linked to more efficient care, high level of veteran satisfaction
Utilization of a teleneurology program by U.S. military veterans resulted in more efficient care compared with the community standard, and resulted in a high level of satisfaction, per research from the Journal of General Internal Medicine.
Rates of new-onset mental health conditions higher in US soldiers with history of TBI
Rates of new-onset mental health conditions were higher in U.S. soldiers with a history of military-related traumatic brain injury, while increased risk for suicide was both directly and indirectly associated with TBI history.
Log in or Sign up for Free to view tailored content for your specialty!
US awards $11.4M for therapeutic to treat Fragile X-associated tremor
The U.S. Department of Defense has awarded $11.4 million to a Boston-based biotherapeutics firm to advance its novel oral prodrug of endogenous allopregananolone, LYT-300, to treat Fragile X-associated Tremor Ataxia syndrome.
NYU Langone named top US hospital for neurology, neurosurgery
NYU Langone Hospitals was named the top hospital in the United States for neurology and neurosurgery by the U.S. News & World Report’s annual Best Hospitals survey.
FDA grants breakthrough designation for Duchenne muscular dystrophy treatment
The FDA has granted breakthrough therapy designation to an investigational antisense nucleotide therapeutic to treat individuals with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
Risk for dementia more than doubled in people diagnosed with depression
The risk for dementia was 2.41 times greater in Danish adults with diagnosed depression, an association that persisted when depression was diagnosed in early and middle life, according to research in JAMA Neurology.
Positive data reported in phase 1/2a studies of therapeutic for pediatric Dravet syndrome
A biotechnology company has announced positive safety and efficacy data from two ongoing phase 1/2a studies as well as an open-label extension study of STK-001 to treat younger individuals with Dravet syndrome.
Phase 2 trial of therapeutic for anxiety initiated
A Southern California-based neuroscience company has announced initiation of a phase 2 clinical trial to evaluate the safety and efficacy of investigational therapeutic ENX-102 in those with generalized anxiety disorder.
Orphan drug designation sought for stem cell therapy to treat frontotemporal dementia
Therapeutic Solutions International has filed with the FDA to receive orphan drug designation for its JadiCell adult stem cell therapy for treatment of frontotemporal dementia.
Neurologist partners with PCPs to elevate care for patients with mental illness
We are in a crisis when it comes to mental health in Alabama. According to the National Alliance on Mental Health, one in five adults in the state lives with mental illness.
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read
-
Headline News
Expected drop in HIV care providers may signal potential shift to primary care physicians
November 11, 20242 min read -
Headline News
Q&A: What to know about surge of ‘walking pneumonia’ in children
November 09, 20244 min read -
Headline News
Racial gaps in preemptive living donor kidney transplant persist during last 2 decades
November 12, 20241 min read